PubMed Health⌕ Search

Biomedical subjects

C A Bentley

Publications and source records attributed to C A Bentley.

7 recordsLinked to original sources
PubMed2000

p75 is important for axon growth and schwann cell migration during development.

Mice lacking the low-affinity neurotrophin receptor p75 have multiple peripheral neural deficits. Here we examined the developmental nature of these deficiencies. Peripheral axons in p75 -/- embryos were severely stunted and poorly arborized from embryonic day 11.5 (E11.5) to E14.5. In vitro, neurite outgrowth from the dorsal root ganglia was significantly decreased in the p75 -/- embryos at E12.5, suggesting that stunted axonal growth in the embryo may result in part from defects in neurite elongation. Additionally, Schwann cell marker S100beta immunoreactivity was decreased or absent along the growing axons of the ophthalmic branch from the trigeminal ganglia in p75 -/- embryos. Electron microscopy studies of the axons of the trigeminal ganglion at E13.5 revealed that in the p75 mutant embryo, nerve bundles were highly impaired and that coverage of the growing axons by Schwann cell cytoplasm was substantially reduced. In vitro, Schwann cell migration from the dorsal root ganglia was significantly decreased in the p75 -/- embryos at E12.5, suggesting that the lack of S100beta staining and Schwann cell coverage in the p75 mutant results from a deficit in Schwann cell migration. These results provide evidence that p75 is important in the developing embryo for regulating axon growth and arborization and for Schwann cell migration.

Animals↗
PubMed1999

Pax6 is implicated in murine pituitary endocrine function.

Pax6, an evolutionarily conserved transcription factor, is expressed in the murine and zebrafish embryonic pituitary, but its role in pituitary development and endocrine function has not been described. To study the role of Pax6 in vivo, we examined Pax6 mutant mouse (SeyNeu) pituitaries. Mice homozygous for the SeyNeu mutation die at birth; therefore, we examined peptide hormone expression by the differentiated pituitary cell types as well as developmental marker expression in the intermediate and anterior lobes of the embryonic pituitary. GH- and PRL-immunopositive cells appear severely decreased in an outbred ICR background at embryonic d 17.5, although mRNA expression of these peptide hormones is present, as is expression of other pituitary markers. This suggests that pituitary cell types are able to differentiate in mutant embryos. To identify the cellular or physiologic mechanism responsible for less GH- and PRL-immunoreactivity in Pax6 mutant mice, we tested serum levels of GH and PRL. Pax6 homozygous mutant mice have GH serum levels one fifth that of controls at embryonic d 17.5, and one-third that of controls at postnatal d 0. PRL serum levels, which are very low during embryonic and neonatal stages, were below assay detection limits in both the wild-type and mutant groups. Taken together, these data suggest that Pax6 is not essential for pituitary differentiation, but rather functions to establish appropriate neonatal homeostatic levels of GH and PRL, possibly through regulation of translational or secretory mechanisms.

Animals↗
PubMed1998

Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development.

Corticotropin releasing factor (CRF) is a major integrator of adaptive responses to stress. Two biochemically and pharmacologically distinct CRF receptor subtypes (CRFR1 and CRFR2) have been described. We have generated mice null for the CRFR1 gene to elucidate the specific developmental and physiological roles of CRF receptor mediated pathways. Behavioral analyses revealed that mice lacking CRFR1 displayed markedly reduced anxiety. Mutant mice also failed to exhibit the characteristic hormonal response to stress due to a disruption of the hypothalamic-pituitary-adrenal (HPA) axis. Homozygous mutant mice derived from crossing heterozygotes displayed low plasma corticosterone concentrations resulting from a marked agenesis of the zona fasciculata region of the adrenal gland. The offspring from homozygote crosses died within 48 hr after birth due to a pronounced lung dysplasia. The adrenal agenesis in mutant animals was attributed to insufficient adrenocorticotropic hormone (ACTH) production during the neonatal period and was rescued by ACTH replacement. These results suggest that CRFR1 plays an important role both in the development of a functional HPA axis and in mediating behavioral changes associated with anxiety.

Adaptation, Physiological↗
PubMed1996

Phage typing and drug resistance of Shigella sonnei isolated in England and Wales.

Phage typing of Shigella sonnei has been used to examine isolates from the 1991-2 sonnei dysentery outbreak in England and Wales and compare them with strains isolated during and following a widespread foodborne outbreak in 1994 which was associated with consumption of imported lettuce. The distribution of phage types was different in the three periods studied with PT 3 predominating during 1991-2, PT 2 during the 'lettuce' outbreak in the summer months and PT 6 during the subsequent months. PT 6 was frequently associated with travel outside the UK. Variation was also seen in the distribution of drug resistance patterns.

Adult↗
PubMed1996

Tissue-specific binding of radiolabeled activin A by activin receptors and follistatin in postimplantation rat and mouse embryos.

Activin affects the growth and differentiation of many cultured cell types, including rat anterior pituitary cells and gonadal and neuronal cell lines. Endogenous activins regulate mesoderm induction, body axis formation, and organogenisis in the developing embryo. The messenger RNAs encoding inhibin/activin subunits, follistatin (an activin-binding protein), and activin type II receptors (ActRII and IIB) are expressed in various cell types and tissues of the embryonic rat and mouse. Follistatin-deficient mice have numerous embryonic defects, including shiny taut skin, allowing relatively easy identification by the later stages of embryogenesis. ActRII-deficient mice, on the other hand, show limited developmental defects, with some (22%) embryonic day 18.5 (E18.5) ActRII-deficient embryos showing various skeletal and facial abnormalities. The present study was undertaken to identify the target tissues for biologically active activin A and assess the significance of its association with ActRII and follistatin in developing rat and mouse embryos. Fresh-frozen, slide-mounted, rat (E13 to E19) and mouse (E18.5) embryo sections were incubated with 125I-labeled recombinant human activin A. Nonspecific binding was evaluated by competition with an excess of cold activin A. As determined by image analysis, the highest levels of activin A binding were observed throughout the brain, spinal cord, and trigeminal and spinal ganglia at all ages. Lower levels of binding were found in the dermis of the skin starting on E15. Follistatin-deficient mice demonstrated similar patterns and levels of activin A binding in the neural tissues compared to wild-type controls, but binding was absent in the skin. In ActRII-deficient mice, activin A binding was completely absent in neural tissues, but was similar to wild-type control levels in the dermal layer of the skin. The data indicate that activin A binds to specific tissues of mouse and rat embryos and that binding is dependent upon the presence of ActRII in the central and peripheral nervous system and on follistatin in the skin.

Activin Receptors↗
PubMed1978

Increased antagonist potency of naloxone caused by morphine pretreatment in mice.

Using the writhing test in mice, it was shown that pretreatment with a single dose of morphine hydrochloride given 3 h previously caused a marked increase in the antagonistic effect of naloxone without any change in the antinociceptive action of morphine itself. It was shown that when mice were pretreated with different doses of either morphine alone, or in combination with naloxone, so that each treatment produced the same antinociceptive effect, the increase in naloxone potency was proportional only to the antinociceptive effect of the pretreatment and not to the total dose of morphine present. It was also found that the concurrent administration of naloxone plus morphine prevented the development of "acute dependence" to morphine, as measured by the jumping reaction after challenge with naloxone.

Analgesics↗